

Amendment 1**Martin Häusling**

on behalf of the Verts/ALE Group

Motion for a resolution**B9-0424/2021****Committee on the Environment, Public Health and Food Safety**

The Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans

Motion for a resolution**Recital O***Motion for a resolution*

O. whereas Articles 112, 113 and 114 of Regulation (EU) 2019/6 allow the off-label use of veterinary and human medicinal products for veterinary purposes under certain conditions; whereas Article 107(6) of Regulation (EU) 2019/6 allows the Commission to restrict off-label use; whereas **there are no** provisions **in** Regulation (EU) 2019/6 **allowing** the use of HRAM for any veterinary purposes;

Amendment

O. whereas Articles 112, 113 and 114 of Regulation (EU) 2019/6 allow the off-label use of veterinary and human medicinal products for veterinary purposes under certain conditions; **whereas Article 107(5) of Regulation (EU) 2019/6 however explicitly rules out the application of those articles for HRAM;** whereas Article 107(6) of Regulation (EU) 2019/6 allows the Commission to restrict off-label use; whereas **in the light of Articles 37(3) and 107(5), the current provisions of Regulation (EU) 2019/6 prohibit** the use of HRAM for any veterinary purposes **without exception;**

Or. en

13.9.2021

B9-0424/2

Amendment 2

Martin Häusling

on behalf of the Verts/ALE Group

Motion for a resolution

B9-0424/2021

Committee on the Environment, Public Health and Food Safety

The Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans

Motion for a resolution

Recital O a (new)

Motion for a resolution

Amendment

Oa. whereas this absolute approach creates a conflict between the interests of human health and those of animal health, which risks being counterproductive with regard to human health concerns and not proportionate with regard to animal health concerns;

Or. en

Amendment 3**Martin Häusling**

on behalf of the Verts/ALE Group

Motion for a resolution**B9-0424/2021****Committee on the Environment, Public Health and Food Safety**

The Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans

Motion for a resolution**Recital BC***Motion for a resolution*

BC. whereas it would be desirable to distinguish between those different applications to achieve the objective of preserving the efficacy of HRAM in the most effective way without causing an undue adverse effect **on** animal **health**; whereas, however, the empowerment in Regulation (EU) 2019/6 does not provide for the possibility to make such a distinction;

Amendment

BC. whereas it would be desirable to distinguish between those different applications to achieve the objective of preserving the efficacy of HRAM in the most effective way without causing an undue adverse effect **with regard to the treatment of individual clinically ill animals (i.e. any animal, be it a companion animal, zoo animal, wild animal or food-producing animal); whereas the term ‘individual’ in this context is meant to encompass several animals, but only those that are clinically ill**; whereas, however, the empowerment in Regulation (EU) 2019/6 does not provide for the possibility to make such a distinction;

Or. en

13.9.2021

B9-0424/4

Amendment 4

Martin Häusling

on behalf of the Verts/ALE Group

Motion for a resolution

B9-0424/2021

Committee on the Environment, Public Health and Food Safety

The Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans

Motion for a resolution

Paragraph 6

Motion for a resolution

6. Calls on the Commission to accompany the new delegated act with a legislative proposal to amend Regulation (EU) 2019/6 to ***set the conditions*** for the treatment of individual animals ***with HRAM by way of derogation from Article 37(3) of that Regulation***;

Amendment

6. Calls on the Commission to accompany the new delegated act with a legislative proposal to amend ***Article 107(5) of Regulation (EU) 2019/6 so as to allow the off-label veterinary use of HRAM*** for the treatment of individual, ***clinically ill animals (i.e. companion animals, zoo animals, wild animals or food-producing animals) under certain conditions***;

Or. en

13.9.2021

B9-0424/5

Amendment 5

Martin Häusling

on behalf of the Verts/ALE Group

Motion for a resolution

B9-0424/2021

Committee on the Environment, Public Health and Food Safety

The Commission delegated regulation of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans

Motion for a resolution

Paragraph 7 a (new)

Motion for a resolution

Amendment

7a. Stresses that the list to be adopted pursuant to Article 37(5) of Regulation (EU) 2019/6 and the amendment of that regulation as referred to in paragraphs 6 and 7 of this resolution should be applicable at the same time;

Or. en